CERo Therapeutics Inc. (CERO)
NASDAQ: CERO
· Real-Time Price · USD
8.10
0.10 (1.25%)
At close: Aug 18, 2025, 10:37 AM
CERo Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 288.16K | 288.16K | 288.16K | 288.16K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -288.16K | -288.16K | -288.16K | -288.16K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -16.6M | -16.2M | -14.47M | -10.5M | -6.89M | -2.93M | -3.85M | -4.26M | -3.09M | -2.91M | -1.95M | -1.11M | -737.81K | -333.03K | -1K |
Interest Income | 850.00 | n/a | 24.51K | 141.61K | 201.03K | 201.05K | 2.66M | 2.86M | 2.84M | 2.85M | 374.85K | 54.38K | 17.27K | n/a | n/a |
Pretax Income | -13.9M | -11.09M | -9.23M | -5.31M | -4.26M | -2.44M | -1.91M | -1.45M | -172.29K | -68.58K | -676.01K | -821.98K | -710.41K | -332.42K | -1K |
Net Income | -13.9M | -11.09M | -9.26M | -5.37M | -5.01M | -5.15M | -5.13M | -4.71M | -2.73M | -667.74K | -719.61K | -805.11K | -693.54K | -315.55K | -1K |
Selling & General & Admin | 8.43M | 9.52M | 8.72M | 6.53M | 5.61M | 2.89M | 3.89M | 4.25M | 3.05M | 2.84M | 1.72M | 934.06K | 607.48K | 252.71K | 1K |
Research & Development | 8.61M | 7.08M | 5.87M | 4.09M | 2.57M | 2.99M | 2.99M | 2.99M | 1.8M | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | -156.25K | -403.89K | -409.14K | -408.04K | -430.74K | -50.55K | 40.65K | -10.45K | -37.75K | -64.05K | -230.32K | -180.32K | -130.32K | -80.32K | n/a |
Operating Expenses | 16.88M | 16.2M | 14.18M | 10.21M | 6.61M | 2.93M | 3.85M | 4.26M | 3.09M | 2.91M | 1.95M | 1.11M | 737.8K | 333.03K | 1K |
Interest Expense | -9.63K | n/a | 26.61K | 26.61K | 9.63K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 403.89K | 403.89K | 403.89K | 704.11K | 228.44K | 228.44K | 228.44K | -71.78K | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 17.47M | 17.07M | 14.47M | 10.5M | 6.89M | 2.93M | 3.85M | 4.26M | 3.09M | 2.91M | 1.95M | 1.11M | 737.81K | 333.03K | 1K |
Income Tax Expense | n/a | n/a | 24.41K | 50.16K | 94.82K | -178.76K | 335.52K | 370.23K | 325.57K | 599.16K | 43.59K | -16.87K | -16.87K | -16.87K | n/a |
Shares Outstanding (Basic) | 1.71M | 1.21M | 248.37K | 80.99K | 73.53K | 2.92K | 45.34K | 45.31K | 45.29K | 33.84K | 114.9K | 114.9K | 114.9K | 114.9K | 116.97K |
Shares Outstanding (Diluted) | 1.71M | 1.21M | 248.37K | 80.99K | 73.53K | 2.92K | 45.34K | 45.31K | 45.29K | 33.84K | 114.9K | 114.9K | 114.9K | 114.9K | 116.97K |
EPS (Basic) | -49.88 | -77.97 | -511.44 | -524.17 | -540.12 | -562.67 | -137.52 | -107.03 | -61.82 | -11.28 | -6.26 | -7.01 | -6.04 | -2.75 | -0.01 |
EPS (Diluted) | -49.88 | -77.97 | -511.44 | -524.17 | -540.12 | -562.67 | -137.52 | -107.76 | -61.59 | -11.05 | -6.03 | -6.04 | -6.04 | -2.75 | -0.01 |
EBITDA | -14.39M | -13.99M | -12.11M | -8.14M | -8M | -5.89M | -5.05M | -4.62M | -2.7M | -781.36K | -1.11M | -1.11M | -736.81K | -332.03K | n/a |
EBIT | -554.71K | n/a | -12.51M | -8.53M | -8.52M | -6.4M | -6.57M | -6.98M | -4.94M | -2.88M | -1.92M | -1.09M | -710.41K | -332.42K | -1K |
Depreciation & Amortization | -311.94K | -293.25K | 572.91K | 1M | 1.28M | 1.27M | 2.27M | 2.68M | 2.4M | 2.12M | 836.68K | 1K | 1K | 1K | 1K |